Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $19.9 million.

  • Ligand Pharmaceuticals' Other Non-Current Liabilities fell 3334.67% to $19.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year decrease of 3334.67%. This contributed to the annual value of $30.2 million for FY2024, which is 866.42% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Other Non-Current Liabilities stood at $19.9 million, which was down 3334.67% from $14.4 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Other Non-Current Liabilities registered a high of $43.7 million during Q3 2023, and its lowest value of $14.2 million during Q1 2025.
  • In the last 5 years, Ligand Pharmaceuticals' Other Non-Current Liabilities had a median value of $27.8 million in 2022 and averaged $25.6 million.
  • In the last 5 years, Ligand Pharmaceuticals' Other Non-Current Liabilities skyrocketed by 9896.12% in 2023 and then plummeted by 5104.43% in 2025.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Other Non-Current Liabilities stood at $21.8 million in 2021, then grew by 27.61% to $27.8 million in 2022, then changed by 0.0% to $27.8 million in 2023, then rose by 8.66% to $30.2 million in 2024, then crashed by 33.99% to $19.9 million in 2025.
  • Its last three reported values are $19.9 million in Q3 2025, $14.4 million for Q2 2025, and $14.2 million during Q1 2025.